BMY · Bristol-Myers Squibb Company
$59.602026-05-17Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Bull
$264
+342.5% vs market
Base · active
$83
+39.6% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($83 · $264) Analysts Range ($40 · $75) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $46.4B | — | 23.8% | 13.4% | $9.6B | $5.6B | $15.2B | 3.2% | — | 10.4% | $91.8B | $3.43 | — |
| 2022.Q4 | $46.2B | -0.5% | 23.3% | 17.7% | $8.8B | $2.0B | $10.8B | 5.1% | — | 9.8% | $89.3B | $3.10 | — |
| 2023.Q4 | $45.0B | -2.5% | 21.8% | 4.7% | $9.4B | $4.4B | $13.8B | 5.1% | — | 10.8% | $84.5B | $3.93 | — |
| 2024.Q4 | $48.3B | 7.3% | 23.2% | 0.0% | $11.9B | −$13.6B | −$1.7B | 6.1% | — | 14.1% | $84.4B | $-4.38 | — |
| 2025.Q4 | $48.2B | -0.2% | 30.5% | 24.4% | $11.1B | −$3.4B | $7.7B | 5.3% | — | 13.4% | $81.7B | $3.46 | 8.3 |
| italics below = DCF projection · 10yr Rev CAGR: 0.7% |
| 2026.Q4 | $46.9B | +-2.7% | 35.4% | 23.9% | $12.6B | $0MM | $12.6B | 5.7% | $11.9B | 15.5% | $81.7B | $4.60 | 13.0 |
| 2027.Q4 | $46.0B | +-2.0% | 34.6% | 23.5% | $12.2B | $0MM | $12.2B | 6.0% | $10.9B | 14.9% | $81.7B | $4.57 | 13.0 |
| 2028.Q4 | $45.4B | +-1.2% | 33.9% | 23.1% | $11.8B | $0MM | $11.8B | 6.3% | $9.9B | 14.5% | $81.7B | $4.57 | 13.0 |
| 2029.Q4 | $45.2B | +-0.5% | 33.1% | 22.6% | $11.6B | $0MM | $11.6B | 6.6% | $9.1B | 14.2% | $81.7B | $4.60 | 13.0 |
| 2030.Q4 | $45.3B | +0.3% | 31.5% | 22.2% | $11.1B | −$1.5B | $9.7B | 6.9% | $7.1B | 13.5% | $83.2B | $4.70 | 12.7 |
|
| Term. Yr+ | $53.6B | 4.1% | 31.5% | 20.0% | $13.5B | −$4.2B | $9.3B | 8.6% | $104.6B | 13.1% | — | — | — |
Active scenario IV: $83 (+39.6% vs market)